Capricor Therapeutics (CAPR) News Today

Shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) have moved lower following an FDA complete response letter on trial design and a wave of shareholder class-action notices. Investors are weighing potential regulatory setbacks as well as legal risks from multiple law firms seeking lead plaintiffs in securities suits.

• Neutral Sentiment: CMC and analytical deficiencies highlighted in a PharmTech review show ongoing gaps in manufacturing and testing despite FDA guidance, underscoring industry-wide challenges rather than company-specific issues. CMC and Analytical Gaps in CRLs
• Neutral Sentiment: July short interest in CAPR remained negligible, with reported figures unchanged and a days-to-cover ratio effectively at zero, suggesting limited speculative pressure in either direction.
• Negative Sentiment: The FDA issued a Complete Response Letter to Capricor regarding trial design deficiencies, joining a similar CRL to Replimune and raising concerns over regulatory delays for Capricor’s pipeline. FDA Crackdown on Trial Design
• Negative Sentiment: Robbins LLP reminded investors of the approaching lead-plaintiff deadline in the Capricor securities class action, signaling mounting legal headwinds. CAPR Class Action Alert (Bakersfield)
• Negative Sentiment: Levi & Korsinsky launched a securities class action notification for shareholders who suffered losses, underscoring significant investor dissatisfaction and potential damages. Levi & Korsinsky Class Action Notice
• Negative Sentiment: Robbins LLP issued a second reminder to Capricor investors about filing deadlines for its securities class action covering purchases from October 2024 through July 2025. CAPR Class Action Alert (GlobeNewswire)
• Negative Sentiment: Faruqi & Faruqi, LLP announced an investigation for investors who lost over $50,000, highlighting potential claims under federal securities laws. Faruqi & Faruqi Investor Deadline Approaching
• Negative Sentiment: Levi & Korsinsky issued a separate PR Newswire reminder of the pending class action with a September 15, 2025 lead plaintiff deadline, underscoring ongoing legal risk. Levi & Korsinsky PR Newswire
• Negative Sentiment: The DJS Law Group filed a securities suit alleging violations of Sections 10(b) and 20(a) of the Exchange Act, further increasing potential liability. DJS Law Group Class Action
• Negative Sentiment: The Gross Law Firm alerted shareholders to a pending class action, reiterating opportunities to act as lead plaintiff in suits over alleged misrepresentations. The Gross Law Firm Class Action
• Negative Sentiment: Bronstein, Gewirtz & Grossman LLC announced that investors with substantial losses may lead a class action, signaling intensified litigation momentum. Bronstein, Gewirtz & Grossman Alert
• Negative Sentiment: A PR Newswire notice by The Gross Law Firm urged shareholders to join a class action, reinforcing persistent legal scrutiny on Capricor’s disclosures. Gross Law Firm PR Newswire